Chemours (NYSE:CC) Stock Price Up 5.6% - Here's What Happened

Key Points

• Chemours Company's stock rose by 5.6% to $17.70 amidst a significant drop in trading volume, reaching only 565,431 shares compared to an average of 3.5 million shares.
• Analyst ratings for Chemours are mixed, with five analysts rating it a Buy, four a Hold, and revisions leading to a price target average of $17.38.
• The company reported a quarterly EPS of $0.58, surpassing estimates and indicating a 5% revenue increase year-over-year, despite a negative net margin of 7.19%.

Shares of The Chemours Company (NYSE:CC - Get Free Report) rose 5.6% on Monday . The company traded as high as $17.59 and last traded at $17.70. Approximately 565,431 shares were traded during trading, a decline of 84% from the average daily volume of 3,507,188 shares. The stock had previously closed at $16.75.

Analyst Upgrades and Downgrades

CC has been the topic of a number of recent analyst reports. Barclays decreased their target price on Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 28th. Zacks Research raised Chemours from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 27th. Royal Bank Of Canada boosted their target price on Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a report on Thursday, July 3rd. Truist Financial boosted their price target on Chemours from $18.00 to $21.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, Mizuho boosted their price target on Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Chemours currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.25.

Chemours Trading Down 3.0%

The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16. The stock has a market capitalization of $2.54 billion, a P/E ratio of -6.07 and a beta of 1.61. The business has a 50-day moving average price of $14.52 and a two-hundred day moving average price of $12.86.

Chemours (NYSE:CC - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. The firm had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.57 billion. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The business's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts expect that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were paid a $0.0875 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.35 annualized dividend and a yield of 2.1%. Chemours's dividend payout ratio is presently -12.50%.

Insider Transactions at Chemours

In other news, CEO Denise Dignam bought 4,068 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $12.06 per share, with a total value of $49,060.08. Following the acquisition, the chief executive officer directly owned 191,546 shares in the company, valued at approximately $2,310,044.76. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.47% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Chemours

A number of institutional investors and hedge funds have recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new position in Chemours during the 1st quarter worth about $27,000. MTM Investment Management LLC bought a new position in Chemours in the second quarter worth approximately $27,000. UMB Bank n.a. boosted its holdings in Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after acquiring an additional 948 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Chemours by 170.7% in the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock worth $30,000 after acquiring an additional 1,444 shares in the last quarter. Finally, SouthState Corp bought a new position in shares of Chemours in the first quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.